Pharmaceuticals distributor Cardinal Health (NYSE:CAH) has launched a web-based tool to help rheumatology practices better manage infusion therapy patients.
Cardinal’s new InfusaTrack software is designed to make it easier for community rheumatology practices to offer in-office infusion therapy, which involves administering medication through a needle or catheter for patients whose conditions are too severe to be treated by oral medication, according to a statement from Dublin, Ohio-based Cardinal.
Administrative burdens of managing infusion therapy patients can make doing so difficult for community rheumatology practices, Cardinal said. Rheumatism refers to diseases characterized by pain and stiffness in the joints, such as arthritis.
The new tool tracks inventories of infused medications, simplifies the process of scheduling patient infusion visits and streamlines the billing process associated with infusion, Cardinal said.
“As new breakthrough treatments for rheumatoid arthritis, lupus, psoriasis and other rheumatic diseases lead to an increased demand for infusion therapy, we’re also seeing an increasing need for tools that help community practices streamline the complicated process of offering this important service to patients,” according to Cardinal’s statement.
What’s in it for Cardinal from a business perspective? The more patients rheumatology practices treat, the more drugs they buy and that boosts Cardinal’s revenues.
A Cardinal spokeswoman said the company charges a monthly fee for the service, but declined to disclose the fee.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
